RE:Time to thinkThe big difference here is that over the last 3 years there was reasonable optimism for 1067 supported by enthusiastic comments by management of a deal by (supposedly) interested partner(s). Either their enthusiasm was feigned or they were just extremely naive, both scenarios are not good. They have no expected upfront revenue for 1067 in their 2018 cash flow projections, which means there is no deal. There has been nothing material accomplished outside of the Wanbang deal in 2012, except for excessive rhetoric about SBM trying to sell more molecules and spending more money on this or that test, or attending this or that conference. There are no fruits to their labour and expenses. If it wasn't for the SGLT2 deal their stock will be worthless. Go ahead Mr. Verrico, prove us wrong and save a thread of credibility to your rhetoric.